New combo aims to stall pancreatic cancer in patients who responded to chemo
NCT ID NCT03404960
First seen Nov 01, 2025 · Last updated May 17, 2026 · Updated 27 times
Summary
This study tested whether adding immunotherapy drugs (ipilimumab or nivolumab) to niraparib can help control advanced pancreatic cancer in people whose disease stopped growing after platinum chemotherapy. About 104 adults with advanced pancreatic cancer took part. The goal was to see how long the cancer stayed under control and how safe the combination was.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Pennsylvania, Abramson Cancer Center
Philadelphia, Pennsylvania, 19104, United States
Conditions
Explore the condition pages connected to this study.